A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes

Purpose:

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Criteria:

Inclusion Criteria: - Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy Exclusion Criteria: - Previous Q-wave infarct within the last 4 weeks - CK elevation not caused by myocardial injury - uncontrolled hypertension at time of randomization

NCT ID:

NCT00214630

Primary Contact:

Study Director
AstraZeneca Crestor Medical Science Director, MD
AstraZeneca

Backup Contact:

N/A

Location Contact:

Atlantis, Florida
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.